Treatment: Therapy is currently limited to symptomatic treatments, such as anti-epileptic drugs for epilepsy for the general IGDs. However, the decreased PIGM expression of the affected individuals with the mutation of the promoter region could be rescued with administration of HDAC inhibitor, sodium butylate, which was very effective to the symptoms of this PIGM deficiency.
PIGM